UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000014440 |
|---|---|
| Receipt number | R000014546 |
| Scientific Title | Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting cobalt-CHromium Stent and platelet AggregatioN studIeS for TreatMent of Acute Myocardial Infarction Identically DeSigned bare-Metal stent in patients with Acute Myocardial Infarction: MECHANISM-AMI |
| Date of disclosure of the study information | 2014/07/01 |
| Last modified on | 2019/03/28 14:00:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting cobalt-CHromium Stent and platelet AggregatioN studIeS
for TreatMent of Acute Myocardial Infarction Identically DeSigned bare-Metal stent in patients with Acute Myocardial Infarction: MECHANISM-AMI
Acronym
MECHANISM-AMI
Scientific Title
Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting cobalt-CHromium Stent and platelet AggregatioN studIeS
for TreatMent of Acute Myocardial Infarction Identically DeSigned bare-Metal stent in patients with Acute Myocardial Infarction: MECHANISM-AMI
Scientific Title:Acronym
MECHANISM-AMI
Region
| Japan |
Condition
Condition
Coronary Artery Disease
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
To evaluate early vessel response between current standard drug-eluting stent and bare-metal stent in acute myocardial infarction (AMI) patients by optical coherence tomography (OCT).
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The percentage of stent strut coverage by OCT at 2-week or 3-months
Key secondary outcomes
Base
Study type
Study design
Basic design
Parallel
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
Everolimus-eluting Cobalt Cromium Stent(CoCr-EES),2-week OCT
Interventions/Control_2
Everolimus-eluting Cobalt Cromium Stent(CoCr-EES),3 month OCT
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | > |
Gender
Male and Female
Key inclusion criteria
- AMI definition is accordance with the third universal definition of ESC /ACCF/ AHA/ WHF Task Force10, detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn) I or T] with at least one value above the 99th percentile upper reference limit (URL) and with at least one of the following:
Symptoms of ischemia.
New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundlebranch block (LBBB).
Development of pathological Q waves in the ECG.
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Identification of an intracoronary thrombus by angiography or autopsy
Of the AMI patients who met the above definition, the criterial for inclusion is limited to STEMI patients. STEMI is defined as new ST elevation at the J point in at least 2 contiguous leads of equal or greater than2 mm (0.2 mV) in men equal or greater than1.5 mm (0.15 mV) in women in leads V2-V3 and/or of equal or greater than 1 mm (0.1 mV) in other contiguous chest leads or the limb leads
-Patients having at least one de novo lesion in a coronary artery in whom PCI with a DES is indicated.
-Patients aged 20 to less than 85 years at the time of informed consent
-Patients who have provided informed consent written by themselves
-Patients who are able to undergo OCT examinations of the site of stent placement at 2 weeks or 3 months and at 12 months
Key exclusion criteria
1) Patients who are judged incapable of undergoing clinical follow-up 12 months after PCI (Consider also the location of patients' residences)
2) Lack of specific findings of ACS by angiography (Left to the operator's decision.)
3) Shock
4) The culprit lesion is the left main coronary trunk
5) Lesion with the reference vascular diameter less than 2.0mm or not less than 4.5mm by visual evaluation.
6) AMI due to stent thrombosis at prior stented segment.
7) Chronic renal failure with serum creatinine level not less than 2.0mg/dl on hospital visit
8) Patients on hemodialysis
9) Cancer patients whose vital prognosis is expected to be within 2 years.
10) Surgery that requires discontinuation of the antiplatelet agent is scheduled within 3 months.
11) Female patient plan to became pregnant or during pregnancy.
12) Patients who experienced adverse reaction to aspirin or clopidogrel (this shall not apply for patients in whom safety of ticlopidine is confirmed)
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshihiro Morino |
Organization
Iwate Medical University
Division name
Division of Cardiology, Department of Internal Medicine
Zip code
Address
19-1 Uchimaru, Morioka, Iwate
TEL
075-751-4255
ymorino@iwate-med.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kanako Omiya |
Organization
The Academic Research Group for Exploring Undiscovered Mechanisms of Cardiovascular Diseases
Division name
Department of cardiovascular medicine
Zip code
Address
19-1 Uchimaru, Morioka, Iwate
TEL
019-651-5111
Homepage URL
komiya@iwate-med.ac.jp
Sponsor or person
Institute
Iwate Medical University
Institute
Department
Personal name
Funding Source
Organization
Abbott Vascular Japan, Co., Ltd.
DAIICHI SANKYO COMPANY, LIMITED
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 07 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2014 | Year | 04 | Month | 22 | Day |
Date of IRB
| 2014 | Year | 02 | Month | 04 | Day |
Anticipated trial start date
| 2014 | Year | 05 | Month | 01 | Day |
Last follow-up date
| 2017 | Year | 05 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2014 | Year | 07 | Month | 01 | Day |
Last modified on
| 2019 | Year | 03 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014546
